Top Markets
#1 Gama Token Gama Token +8.47%
#2 Audiera Audiera +4.73%
#3 Cross Cross +4.30%
#4 Palladium Network Palladium Network +3.83%
#5 Ontology Gas Ontology Gas +3.45%
#6 Akedo Akedo +3.26%
#7 Ribbita by Virtuals Ribbita by Virtuals +3.05%
#8 Holoworld Holoworld +2.58%
#9 OKZOO OKZOO +2.40%
#10 Tutorial Tutorial +2.30%
Coin of the day
Gama Token Gama Token
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Rangering i aksjer #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aksjekurs
$1.73
Sist synkronisert: 2025-06-17
Markedsverdi
$2.55M
Endring (1 dag)
-0.29%
Endring (1 år)
0.00%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)

Kategori

Healthcare
Inntekter for Eiger BioPharmaceuticals, Inc. (EIGR)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Eiger BioPharmaceuticals, Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Eiger BioPharmaceuticals, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE